687 related articles for article (PubMed ID: 22503610)
1. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
[TBL] [Abstract][Full Text] [Related]
5. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
Matsui K; Kim-Mitsuyama S; Ogawa H; Jinnouchi T; Jinnouchi H; Arakawa K;
Hypertens Res; 2014 Jun; 37(6):526-32. PubMed ID: 24599010
[TBL] [Abstract][Full Text] [Related]
7. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Ogihara T; Saruta T; Rakugi H; Shimamoto K; Ito S; Matsuoka H; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Saito I; Shimada K;
Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
10. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
12. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
Ruilope LM; Schaefer A
Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
[TBL] [Abstract][Full Text] [Related]
14. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
[TBL] [Abstract][Full Text] [Related]
15. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
[TBL] [Abstract][Full Text] [Related]
17. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
[TBL] [Abstract][Full Text] [Related]
18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
20. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
